First Trust Nasdaq Pharmaceuticals ETF
First Trust Nasdaq Pharmaceuticals ETF reported 50 holdings worth US$36.2M as of Jun 30, 2026 (Form N-PORT)
As of Jun 30, 2026 · Filed Aug 21, 2026
First Trust Nasdaq Pharmaceuticals ETF reported 50 holdings worth US$36.2M as of Jun 30, 2026. Largest: Eli Lilly And Company, Abbvie Inc. and Merck & Company, Inc. Filed Aug 21, 2026 (Form N-PORT).
- Holdings
- 50
- Value as reported
- US$36.2M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Eli Lilly And Company | 2,347 | US$2.82M | 7.8% |
| Abbvie Inc. | 10,640 | US$2.68M | 7.4% |
| Merck & Company, Inc. | 19,942 | US$2.56M | 7.1% |
| Johnson & Johnson | 9,939 | US$2.52M | 7.0% |
| Bristol-myers Squibb Company | 39,590 | US$2.28M | 6.3% |
| Biogen Inc. | 6,436 | US$1.39M | 3.8% |
| Viatris Inc. | 82,694 | US$1.31M | 3.6% |
| Cardinal Health, Inc. | 5,386 | US$1.28M | 3.5% |
| Vertex Pharmaceuticals Incorporated | 2,485 | US$1.23M | 3.4% |
| Amgen Inc. | 3,181 | US$1.15M | 3.2% |
| Pfizer, Inc. | 44,652 | US$1.08M | 3.0% |
| Gilead Sciences, Inc. | 8,289 | US$1.05M | 2.9% |
| United Therapeutics Corporation | 1,822 | US$987K | 2.7% |
| Regeneron Pharmaceuticals, Inc. | 1,579 | US$985K | 2.7% |
| Jazz Pharmaceuticals Plc | 3,741 | US$901K | 2.5% |
| Incyte Corporation | 7,648 | US$867K | 2.4% |
| Illumina, Inc. | 4,088 | US$719K | 2.0% |
| Zoetis Inc. | 9,417 | US$677K | 1.9% |
| Exelixis, Inc. | 11,488 | US$625K | 1.7% |
| Charles River Laboratories International, Inc. | 2,377 | US$539K | 1.5% |
| Medpace Holdings, Inc. | 966 | US$512K | 1.4% |
| Ptc Therapeutics, Inc. | 6,091 | US$497K | 1.4% |
| Neurocrine Biosciences, Inc. | 2,939 | US$495K | 1.4% |
| Alkermes Plc | 9,366 | US$491K | 1.4% |
| Halozyme Therapeutics, Inc. | 5,593 | US$438K | 1.2% |
| Biomarin Pharmaceutical Inc. | 7,061 | US$404K | 1.1% |
| Twist Bioscience Corporation | 3,619 | US$372K | 1.0% |
| Spyre Therapeutics, Inc. | 3,948 | US$351K | 0.97% |
| Travere Therapeutics, Inc. | 5,700 | US$324K | 0.89% |
| Tg Therapeutics, Inc. | 5,643 | US$310K | 0.86% |
| Elanco Animal Health Incorporated | 12,210 | US$300K | 0.83% |
| 10x Genomics, Inc. | 7,367 | US$282K | 0.78% |
| Guardant Health, Inc. | 1,808 | US$271K | 0.75% |
| Ligand Pharmaceuticals Incorporated | 856 | US$271K | 0.75% |
| Arcus Biosciences, Inc. | 8,336 | US$257K | 0.71% |
| Amneal Pharmaceuticals, Inc. | 14,511 | US$251K | 0.69% |
| Arrowhead Pharmaceuticals, Inc. | 2,918 | US$238K | 0.66% |
| Catalyst Pharmaceuticals, Inc. | 7,357 | US$231K | 0.64% |
| Krystal Biotech, Inc. | 616 | US$229K | 0.63% |
| Protagonist Therapeutics, Inc. | 1,844 | US$226K | 0.62% |
| Moderna, Inc. | 3,170 | US$222K | 0.61% |
| Mirum Pharmaceuticals, Inc. | 1,840 | US$215K | 0.59% |
| Kymera Therapeutics, Inc. | 1,859 | US$213K | 0.59% |
| Roivant Sciences Ltd. | 5,868 | US$208K | 0.57% |
| Acadia Pharmaceuticals Inc. | 6,914 | US$175K | 0.48% |
| Ionis Pharmaceuticals, Inc. | 2,093 | US$166K | 0.46% |
| Arcutis Biotherapeutics, Inc. | 6,296 | US$165K | 0.46% |
| Alnylam Pharmaceuticals, Inc. | 510 | US$154K | 0.42% |
| Supernus Pharmaceuticals, Inc. | 3,103 | US$144K | 0.40% |
| Tarsus Pharmaceuticals, Inc. | 2,249 | US$142K | 0.39% |
Source
View original at SEC
Related